Clinical Trial Detail

NCT ID NCT02260661
Title Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors AstraZeneca
Indications

Advanced Solid Tumor

Her2-receptor negative breast cancer

Therapies

Fulvestrant

AZD8835

Age Groups: adult

Additional content available in CKB BOOST